Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 14

1.

Glycogen synthase kinase-3 inhibition induces glioma cell death through c-MYC, nuclear factor-kappaB, and glucose regulation.

Kotliarova S, Pastorino S, Kovell LC, Kotliarov Y, Song H, Zhang W, Bailey R, Maric D, Zenklusen JC, Lee J, Fine HA.

Cancer Res. 2008 Aug 15;68(16):6643-51. doi: 10.1158/0008-5472.CAN-08-0850.

2.

Glycogen synthase kinase 3 (GSK3) in the heart: a point of integration in hypertrophic signalling and a therapeutic target? A critical analysis.

Sugden PH, Fuller SJ, Weiss SC, Clerk A.

Br J Pharmacol. 2008 Mar;153 Suppl 1:S137-53. doi: 10.1038/sj.bjp.0707659. Epub 2008 Jan 21. Review.

3.
4.

The role of Myc and let-7a in glioblastoma, glucose metabolism and response to therapy.

Wang G, Wang J, Zhao H, Wang J, Tony To SS.

Arch Biochem Biophys. 2015 Aug 15;580:84-92. doi: 10.1016/j.abb.2015.07.005. Epub 2015 Jul 4. Review.

PMID:
26151775
5.

Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions.

Jope RS, Roh MS.

Curr Drug Targets. 2006 Nov;7(11):1421-34. Review.

6.

Innate and adaptive immune responses regulated by glycogen synthase kinase-3 (GSK3).

Beurel E, Michalek SM, Jope RS.

Trends Immunol. 2010 Jan;31(1):24-31. doi: 10.1016/j.it.2009.09.007. Epub 2009 Oct 14. Review.

7.

Is glycogen synthase kinase-3 a central modulator in mood regulation?

Li X, Jope RS.

Neuropsychopharmacology. 2010 Oct;35(11):2143-54. doi: 10.1038/npp.2010.105. Epub 2010 Jul 28. Review.

8.

Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases.

Beurel E, Grieco SF, Jope RS.

Pharmacol Ther. 2015 Apr;148:114-31. doi: 10.1016/j.pharmthera.2014.11.016. Epub 2014 Nov 27. Review.

9.

Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics.

Jope RS, Yuskaitis CJ, Beurel E.

Neurochem Res. 2007 Apr-May;32(4-5):577-95. Epub 2006 Aug 30. Review.

10.

Mitochondrial energy metabolism and apoptosis regulation in glioblastoma.

Nagy A, Eder K, Selak MA, Kalman B.

Brain Res. 2015 Jan 21;1595:127-42. doi: 10.1016/j.brainres.2014.10.062. Epub 2014 Nov 4. Review.

PMID:
25451120
11.

MYC-mediated synthetic lethality for treating tumors.

Li X, Zhang XA, Li X, Xie W, Huang S.

Curr Cancer Drug Targets. 2015;15(2):99-115. Review.

PMID:
25553514
12.

MYC-mediated synthetic lethality for treatment of hematological malignancies.

Li X, Zhang XA, Xie W, Li X, Huang S.

Curr Cancer Drug Targets. 2015;15(1):53-70. Review.

PMID:
25564254
13.

Chronic over-nutrition and dysregulation of GSK3 in diseases.

Liu X, Yao Z.

Nutr Metab (Lond). 2016 Aug 4;13:49. doi: 10.1186/s12986-016-0108-8. eCollection 2016. Review.

14.

MYC and mitochondrial biogenesis.

Morrish F, Hockenbery D.

Cold Spring Harb Perspect Med. 2014 May 1;4(5). pii: a014225. doi: 10.1101/cshperspect.a014225. Review.

Items per page

Supplemental Content

Write to the Help Desk